Argentina’s ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is the national authority that must grant prior authorization before most drug and biologic clinical trials can begin in the country. For sponsors and CROs weighing Argentina against other Latin American sites, the practical questions are the same ones that matter for any regulatory pathway: which trial phases actually require ANMAT’s sign-off, how long a decision legally takes, and whether a faster track exists.
What ANMAT Authorizes, and What It Doesn’t
ANMAT’s authority over clinical pharmacology studies now runs through Disposición ANMAT N° 7516/2025, issued October 8, 2025, published in the Boletín Oficial on October 9, 2025, and effective December 1, 2025. It repeals the regime that had governed trial authorization since 2010 (Disposición 6677/2010 and its subsequent modifications, Disposiciones 4008/2017, 9929/2019, and 2172/2025) and replaces it with a single consolidated framework.
Under Article 4 of Disposición 7516/2025, the rule applies to clinical pharmacology studies conducted for registration purposes, and to studies of already-registered medicines evaluating a new indication, a higher concentration than the one already registered, a new dosage regimen, a new pharmaceutical form, or any other post-registration change that requires clinical trial data to support it. Specifically:
- Phase I, II, and III studies, and phase variations conducted for registration purposes, fall within scope and require ANMAT’s prior authorization before the study can proceed.
- Bioequivalence and bioavailability studies are explicitly excluded from this framework — they’re governed by ANMAT’s separate, dedicated bioequivalence regulations.
- Non-interventional studies and studies conducted without a registration purpose fall outside the rule entirely.
Article 4 is direct on the authorization requirement itself: sponsors must request ANMAT’s authorization before conducting any study covered by the disposición, and must satisfy the requirements the disposición sets out. Separately, under Argentina’s Código Civil y Comercial de la Nación (Articles 58-59, in force since August 2015), any human-subjects research protocol nationally requires both prior approval from an accredited research ethics committee and prior authorization from the competent public authority — reinforcing ANMAT’s authorization role as a matter of general civil law, not just sector regulation.
The Statutory Decision Window — and Why the Number Has Moved Over Time
Argentina’s ANMAT timeline has been reformed more than once, and sponsors researching this pathway will find different day-counts depending on which regulatory generation a given source describes:
- The 2010 baseline. Under the original Disposición 6677/2010 regime, legal summaries of Argentina’s clinical trials framework commonly cited a 90-business-day statutory window for ANMAT to issue a decision from the date a complete application was submitted — a period that could be suspended if ANMAT raised an objection or requested additional documentation, with the clock resuming only once the sponsor responded.
- The 2017 reform. Disposición ANMAT 4008/2017 (April 26, 2017) restructured the review into a standard track of 70 working days (60 days of technical evaluation plus 10 administrative days) and an expedited track of 55 working days (45 technical plus 10 administrative) for protocols that had already been evaluated and approved, and were actively running, in a defined list of reference countries — the 2017 disposición’s Annex I named the United States, Japan, Sweden, Switzerland, Israel, Canada, Austria, Germany, France, the United Kingdom, the Netherlands, Belgium, Denmark, Spain, and Italy. This was framed at the time as a major acceleration from a prior baseline closer to 160 business days.
- What sponsors are now describing as a “62-day” framework. Industry trial-accelerator commentary tracking Latin America’s regulatory modernization (2025-2026) has begun referring to Argentina’s authorization process in the low-60-business-day range as part of ANMAT’s continued streamlining — alongside a new electronic submission platform intended to compress review cycles further. This specific figure could not be independently confirmed against ANMAT’s own published text: Disposición 7516/2025’s operative articles (Articles 1-9, reviewed directly from the Boletín Oficial) establish the new authorization framework and adopt ICH E6(R3), but the procedural day-counts and any expedited-track eligibility criteria are set out in Annexes I-VI, which are published separately on the Boletín Oficial’s web edition and were not independently verified for this guide. Sponsors should confirm the current, binding timeline directly against ANMAT’s published annexes or ANMAT’s own site before building a submission schedule around any specific day-count reported in secondary sources, this one included.
One mechanism is confirmed directly in the new disposición’s operative text: Article 5(r) gives ANMAT’s Directorate of Clinical Research and Drug Registry Management standing authority to propose operational procedures that modify timeframes and processes — including “autorización expeditiva” (expedited authorization) and “evaluación abreviada” (abbreviated evaluation) — specifically for declared health emergencies. That’s a narrower, emergency-triggered fast track, distinct from any general expedited pathway tied to prior approval in reference countries.
ICH E6(R3) Adoption and the Ethics Committee Layer
A substantive change in Disposición 7516/2025, not just a timeline one, is Article 3’s formal adoption of the ICH E6(R3) Good Clinical Practice guideline for registrational clinical pharmacology trials in Argentina, layered with local regulatory requirements set out in the disposición’s Annex II. This follows Argentina’s accession as a full ICH Regulatory Member (for the technical requirements applicable to pharmaceuticals for human use) in June 2024, and builds on ANMAT’s 2017 recognition by the Pan American Health Organization (PAHO/OPS) as a Regional Reference National Regulatory Authority for medicines and vaccines — the designation PAHO uses to identify the region’s more mature, benchmark regulatory agencies.
ANMAT’s authorization runs in parallel with, not instead of, independent ethics review. A protocol cannot proceed without approval from an accredited Independent Ethics Committee, operating under the framework set by Ministry of Health Resolution 1480/2011 (the “Guía para Investigaciones en Salud Humana”), and informed consent must meet the standard set in Article 59 of the Código Civil y Comercial — a “clear, precise, and adequate” disclosure the participant must receive and understand before consenting. ANMAT’s Directorate of Clinical Research also runs its own site inspections for first-in-human studies and continuing GCP oversight of investigators, sponsors, and contract research organizations throughout the trial.
MedTech, Biopharma, and Why the Timeline Matters Commercially
The timeline reforms sit inside a broader push to position Argentina competitively for international trial placement. ANMAT’s PAHO reference-authority status and its 2024 ICH membership are both explicitly framed, in the disposición’s own recitals, as tools for facilitating Argentina’s participation in international multi-site research and for optimizing regulatory processes — language aimed squarely at sponsors deciding where to place global Phase II/III programs. Industry coverage of Latin America’s regulatory environment has increasingly grouped Argentina with Brazil and Mexico as a market attracting growing MedTech and biopharma clinical-development investment, driven by a combination of high enrollment rates, an established base of GCP-experienced investigators and sites, and the region’s comparatively lower per-patient trial costs relative to the US and Western Europe. A predictable, harmonized (ICH-aligned) authorization pathway is a direct input into that competitiveness case — sponsors weighing a multi-country Latin American trial footprint are comparing statutory review windows across jurisdictions as one factor in site selection.
How Argentina Compares to Other Regional Pathways
Argentina is one of several Latin American jurisdictions that have reformed their clinical trial authorization frameworks in recent years. For sponsors building a regional submission strategy, see CASRAI’s companion guides on ANVISA’s clinical trial approval pathway in Brazil and COFEPRIS’s clinical trial authorization pathway in Mexico, as well as the broader survey of international pathways in the clinical research cluster hub, which also covers North American, European, and Asia-Pacific frameworks including Health Canada’s clinical trial framework, India’s CDSCO pathway, and Switzerland’s Swissmedic/ClinO framework.
Frequently Asked Questions
Does every clinical trial in Argentina need ANMAT authorization?
No. ANMAT’s prior-authorization requirement under Disposición 7516/2025 applies to Phase I, II, and III clinical pharmacology studies conducted for registration purposes (and registration-relevant post-approval changes to already-registered products). Bioequivalence/bioavailability studies, non-interventional studies, and studies without a registration purpose fall outside this specific framework and are governed separately.
What happened to the older “90 business days” figure?
That figure is commonly cited in legal summaries of the original 2010-era ANMAT framework. It was substantially revised by the 2017 reform (Disposición 4008/2017), which introduced a 70-working-day standard track and a 55-working-day expedited track for studies already running in a defined set of reference countries, and again by Disposición 7516/2025, effective December 1, 2025, which repealed the entire prior regulatory chain. Sponsors should treat older sources citing 90 days as describing a framework that no longer governs new submissions.
Is the “62-day” authorization framework confirmed by ANMAT directly?
The operative articles of Disposición 7516/2025 establish the new authorization and ICH E6(R3)-aligned framework but do not themselves state a specific day-count for standard or expedited review — that level of procedural detail sits in the disposición’s annexes. Industry trial-accelerator commentary describes Argentina’s current review process as landing in that range, but this guide could not independently verify the figure against ANMAT’s published annex text, and recommends confirming the current binding timeline directly with ANMAT or a local regulatory counsel before relying on it for a submission schedule.
Does Phase IV research ever need ANMAT prior authorization?
Historically, under the pre-2025 framework, Phase IV protocols required ANMAT prior authorization only in specific circumstances, such as designs using a placebo control group. Disposición 7516/2025’s Article 4 defines its own scope around Phase I-III studies and registration-relevant post-approval changes; sponsors planning a Phase IV or post-marketing study in Argentina should confirm current applicability directly with ANMAT, since the boundary between what requires this framework’s authorization and what falls under other ANMAT post-marketing surveillance rules is a scope question specific to the study design.
This guide reflects ANMAT Disposición 7516/2025 as published in Argentina’s Boletín Oficial and other cited primary and industry sources as of this writing. Clinical trial regulatory timelines are periodically revised — confirm current requirements directly with ANMAT before finalizing a submission plan.
